Pulmonology · Chronic Obstructive Pulmonary Disease
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The diagnosis of COPD is confirmed by spirometry showing a post-bronchodilator FEV1/FVC ratio < 0.70.
Smoking cessation and long-term oxygen therapy (if PaO2 ≤ 55 mmHg or SaO2 ≤ 88%) are the only interventions proven to increase survival.
GOLD guidelines recommend long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) as the first-line maintenance therapy for symptomatic patients.
Acute exacerbations of COPD are most commonly triggered by viral or bacterial respiratory infections and are managed with systemic corticosteroids, antibiotics, and bronchodilators.
Alpha-1 antitrypsin deficiency should be suspected in patients who develop panacinar emphysema at a young age (< 45 years) or in the absence of a smoking history.
Non-invasive positive pressure ventilation (NIPPV) is the preferred initial ventilatory support for patients with acute respiratory failure due to COPD exacerbation to reduce the need for intubation.
Inhaled corticosteroids are indicated as an add-on therapy only for patients with a history of frequent exacerbations or high blood eosinophil counts.
Vignette unlocked
A 68-year-old male with a 50-pack-year smoking history presents to the emergency department with increased dyspnea, productive cough with yellow sputum, and wheezing. On physical exam, he has prolonged expiration, barrel chest, and pursed-lip breathing. His oxygen saturation is 86% on room air. Arterial blood gas reveals respiratory acidosis with a pH of 7.28 and a PaCO2 of 65 mmHg.
What is the most appropriate initial ventilatory management for this patient?
Non-invasive positive pressure ventilation (NIPPV)
This patient is experiencing an acute COPD exacerbation with respiratory failure; NIPPV is the first-line intervention to improve gas exchange and prevent the complications associated with invasive mechanical ventilation.
Full handout
High yield triage
Etiology / Epidemiology
Primary risk factor is cigarette smoking; consider alpha-1 antitrypsin deficiency in young patients with panacinar emphysema.
Clinical Manifestations
Presents with chronic cough and dyspnea; pink puffers (emphysema) vs blue bloaters (chronic bronchitis).
Diagnosis
Spirometry showing FEV1/FVC < 0.70 post-bronchodilator is the diagnostic threshold.
Treatment
Tiotropium (LAMA) is the preferred maintenance therapy; avoid non-selective beta-blockers (cardioselective agents are safe) in acute exacerbations.
Prognosis
Long-term oxygen therapy is the only intervention proven to increase survival in hypoxemic patients.
Full handout
Epidemiology & Etiology
COPD is primarily driven by tobacco smoke exposure, causing irreversible airway obstruction. In patients <45 years old or those without smoking history, suspect alpha-1 antitrypsin deficiency. Occupational dust and chemical fumes are secondary contributors.
Pertinent Anatomy
Emphysema involves destruction of alveolar walls distal to the terminal bronchioles, leading to loss of elastic recoil. Chronic bronchitis involves inflammation of the bronchi with mucus hypersecretion. The resulting hyperinflation flattens the diaphragm on imaging.
Pathophysiology
Chronic inflammation leads to airway remodeling and loss of alveolar surface area. This causes air trapping and increased residual volume. Ventilation-perfusion (V/Q) mismatch results in hypoxemia and hypercapnia, driving the clinical syndrome.
Clinical Manifestations
Patients present with progressive dyspnea and chronic productive cough. Physical exam reveals barrel chest, prolonged expiratory phase, and wheezing. Acute respiratory failure is signaled by altered mental status or accessory muscle use.
Diagnosis
Spirometry is the gold standard for diagnosis, confirming FEV1/FVC < 0.70. Chest X-ray may show hyperinflation and a flattened diaphragm, but is primarily used to rule out other pathologies.
Treatment
Smoking cessation is the most important intervention. Tiotropium (LAMA) is the first-line maintenance agent. Systemic corticosteroids are indicated for acute exacerbations, but avoid long-term use due to side effects.
Prognosis
Patients are at high risk for cor pulmonale and secondary polycythemia. Long-term oxygen therapy is indicated if resting PaO2 ≤ 55 mmHg or SaO2 ≤ 88%.
Differential Diagnosis
Asthma: reversible airway obstruction
Bronchiectasis: daily mucopurulent sputum and hemoptysis
Congestive Heart Failure: elevated BNP and pulmonary edema
Tuberculosis: night sweats and apical cavitary lesions
Lung Cancer: weight loss and hemoptysis